DISCOVER-ME Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)
- Coordinator
- Medizinische Universitaet Wien, Austria
- Runs
- 1 July 2026 to 30 June 2030
- Status
- Running
- EU funding
- €7.6m
- Total cost
- €7.6m
- Partners
- 21 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287766
What the project is doing
In the project's own words, from its summary on CORDIS.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem disease affecting up to 1% of the population. It is defined by post-exertional malaise, persistent fatigue, cognitive and neurological symptoms, and autonomic, endocrine, and immune dysfunction. Clinical heterogeneity and the absence of specific diagnostic tests lead to long delays in diagnosis, lack of effective therapies, and a socioeconomic burden exceeding €40 billion annually in Europe.
DISCOVER-ME will deliver the first clinically actionable, biologically validated stratification framework for ME/CFS. Through harmonised clinical phenotyping of 2,000 patients and multi-omics profiling of >900 samples from five European biobanks, the project will identify, validate, and prioritise biomarkers across (epi)genetic, immune, metabolic, neuroendocrine, and vascular domains. This large-scale, reproducible approach overcomes decades of fragmented, underpowered studies that have stalled progress.
Three innovations set DISCOVER-ME apart: (i) a robust biomarker discovery and validation pipeline; (ii) the first systems-level taxonomy of ME/CFS grounded in mechanistic disease drivers and supported by AI-assisted stratification; and (iii) open-access disease maps and digital twin models that combine biological mechanisms with social and economic determinants of health, enabling in silico testing of therapeutic hypotheses.
These outputs will underpin biomarker-guided clinical trials and precision drug repurposing. Patient involvement is embedded throughout—from co-design of phenotyping tools to surveys, stratification frameworks, and policy recommendations—ensuring that lived experience informs all biomedical and computational outputs. By integrating patient, clinical, and biological perspectives, DISCOVER-ME will deliver evidence and tools directly relevant to patients, clinicians, and health systems.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Universitaet Wien | Wien | Austria | Coordinator |
| Delta 4 GmbH | Wien | Austria | Participant |
| Fh Joanneum Gesellschaft Mbh | Graz | Austria | Participant |
| The University of Western Ontario | Ontario - London | Canada | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Remedical Me Aps | Copenhagen | Denmark | Participant |
| Idryma Technologias Kai Erevnas | Irakleio | Greece | Participant |
| Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana | Valencia | Spain | Participant |
| Fundacion Universidad Catolica De Valencia San Vicente Martir | Valencia | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Universite De Toulouse | Toulouse | France | Third party |
| University of Galway | Galway | Ireland | Participant |
| Landspitali University Hospital | Reykjavik | Iceland | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Institute for Cardiovascular Diseases ""Dedinje"""" | Belgrade | Serbia | Participant |
| European Me Alliance Emea | Stockholm | Sweden | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| Cardiff University | Cardiff | United Kingdom | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Participant |
| London School of Hygiene and Tropical Medicine Royal Charter | London | United Kingdom | Participant |
| Quadram Institute Bioscience | Norwich | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI